Insilico Medicine, whose Hong Kong IPO application lapsed in 2024, is still considering going public in the city, said ...

The New Normal Five years ago, COVID-19 was declared a global pandemic, marking the official onset of a healthcare crisis ...

Pheiron and Ribo are excited to announce that the first two strategic collaboration milestones have been successfully ...

The Chinese health care technology sector is in the midst of a transformative phase, fueled by breakthroughs in artificial ...

Orphan Drug Designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenström ...

For more information on the Phase 1b clinical trial, visit: https://clinicaltrials.gov/study/NCT06732180 ...

Explore why Recursion Pharmaceuticals' AI-driven drug discovery faces challenges in revenue growth, governance, and investor ...

Roche has announced the launch of a new cardiovascular, renal and metabolism (CVRM) hub at Harvard’s Enterprise Research ...

Learn more about whether Recursion Pharmaceuticals, Inc. or Zai Lab Limited is a better investment based on AAII's A+ ...

Medera is a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a range of next-generation therapeutics. Medera operates via ...

Noon, is tackling ALS and other neurological disorders with a bold, multi-targeted approach. Fueled by a personal encounter ...